Inquiry Basket
CAS No.:
Cat No.: BADC-00782
4.5 
Spliceostatin C is a potent ADC payload targeting spliceosome function, leading to cancer cell apoptosis. Incorporated in antibody-drug conjugates, it improves targeted chemotherapy effectiveness.
Structure of
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Spliceostatin C is a natural product-derived cytotoxin and a potent ADC payload utilized in antibody-drug conjugates for targeted cancer therapy. Its cytotoxic mechanism involves inhibition of the spliceosome complex, leading to disruption of pre-mRNA splicing and accumulation of unprocessed transcripts, which triggers apoptosis in proliferating tumor cells. The molecular structure of Spliceostatin C allows conjugation to antibodies via cleavable or non-cleavable linkers for site-specific delivery.
In antibody-drug conjugates, Spliceostatin C is linked to monoclonal antibodies through linker chemistries that provide systemic stability and controlled intracellular release. The ADC remains inactive during circulation and is activated upon internalization into target cells expressing the relevant antigen. This selective release mechanism ensures that spliceosome inhibition occurs specifically in tumor cells, minimizing systemic toxicity while maintaining cytotoxic efficacy.
Applications of Spliceostatin C include its integration into ADCs targeting hematologic malignancies and solid tumors. Its chemical compatibility with various linker systems facilitates optimization of conjugation efficiency, payload stability, and intracellular release kinetics. Spliceostatin C demonstrates reproducible cytotoxic activity in spliceosome-dependent cancer cells, supporting the development of ADCs with defined mechanisms of action and targeted antitumor effects.
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-00780 | Spliceostatin A | 391611-36-2 | |
| BADC-00781 | Spliceostatin B |
What is Spliceostatin C?
Spliceostatin C is a potent splicing inhibitor used as an ADC payload. It targets the spliceosome machinery, disrupting RNA processing and leading to apoptosis in cancer cells. This mechanism allows selective elimination of rapidly dividing tumor cells when delivered via ADCs.
23/8/2021
We would like to know how Spliceostatin C contributes to ADC selectivity.
When conjugated to antibodies, Spliceostatin C is delivered specifically to antigen-positive cells. Its selective intracellular release disrupts RNA splicing only in target cells, enhancing therapeutic specificity while limiting systemic cytotoxicity.
7/11/2019
We are interested in knowing which linker strategies are compatible with Spliceostatin C.
Spliceostatin C can be conjugated using cleavable linkers sensitive to intracellular conditions. These linkers allow controlled release of the cytotoxin within the target cell, optimizing ADC stability in circulation and therapeutic potency.
12/9/2022
May I ask if Spliceostatin C can be used for preclinical ADC evaluation?
Yes, Spliceostatin C is commonly employed in preclinical ADC studies to assess cytotoxicity, efficacy, and pharmacokinetics. These studies provide essential data for ADC optimization and subsequent clinical development.
13/3/2017
Good morning! What precautions are required for handling Spliceostatin C?
Handling Spliceostatin C necessitates strict safety measures, including PPE, proper containment, and controlled disposal. Due to its potent activity on RNA splicing, laboratory protocols must be rigorously followed to prevent exposure.
27/4/2020
— Dr. Richard Evans, Senior Scientist (USA)
Spliceostatin C delivered by BOC Sciences showed exceptional purity and batch reproducibility.
12/9/2022
— Dr. Angela Morris, Molecular Biologist (USA)
Spliceostatin C was supplied with high purity, and its consistent performance made it an excellent choice for mechanistic studies.
27/4/2020
— Mr. Philippe Martin, Research Manager (France)
The availability of Spliceostatin C from BOC Sciences was a key factor in accelerating our project milestones.
13/3/2017
— Ms. Lena Fischer, Scientist (Germany)
Spliceostatin C maintained stability under our storage and assay conditions, ensuring reproducibility of results.
23/8/2021
— Dr. George Allen, R&D Lead (UK)
The detailed certificate of analysis provided with Spliceostatin C gave us confidence in its application for ADC design.
— Ms. Isabella Conti, ADC Researcher (Italy)
We valued the strong technical support accompanying Spliceostatin C, which allowed us to optimize its use effectively.
7/11/2019
Spliceostatin C
Required fields are marked with *
Spliceostatin C
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
